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Edited by Varda RotterAbstract Kru¨ppel-like factor 6 (KLF6) is a cancer gene
(www.sanger.ac.uk/genetics/CGP/Census/). Here, we demon-
strate that KLF6 protein is rapidly degraded when apoptosis is
induced via the intrinsic pathway by cisplatin, adriamycin, or
UVB irradiation in multiple cell lines (HCT116, SW40, HepG2,
PC3-M, Skov3, NIH-3T3, 293T, GM09706, and MEF, IMR-
90). KLF6 degradation occurred in the presence or absence of
p53, was associated with ubiquitination, mediated by the protea-
some (half-life 16 min, unstimulated), and independent of casp-
ases and calpain. KLF6 was unchanged by apoptosis via the
extrinsic/death-receptor pathway. Deregulation of KLF6 stabil-
ity may alter its tumor suppressor function and/or the response
of tumors to chemotherapeutics.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Kru¨ppel-like factor 6 (KLF6) is a member of the Kru¨ppel-
like family of C2H2 zinc ﬁnger transcription factors and has
been linked to carcinogenesis by a high rate of somatic muta-
tions in malignancies of the prostate, colon, stomach, liver,
lung, neck, pituitary, and nervous system [1–6]. Decreased
expression of KLF6 has been associated with poor prognosis
in adenocarcinoma of the lung [7] and in prostate cancer [8].
We recently reported that a germline single nucleotide poly-
morphism (SNP) in the KLF6 gene increases the risk for pros-
tate cancer in men with a family history of this disease, thereby
linking KLF6 to an inheritable cancer syndrome [9].
We have previously demonstrated that KLF6 contributes to
cell cycle regulation via transcriptional activation of the p21
promoter, as well as direct sequestration of cyclin D1 protein
through competition with cdk4. It also inhibits transcription
of c-jun [2,10,11]. All of these activities induce G1 arrest and
a decrease in cell proliferation. However, little else is known*Corresponding author. Fax: +1 212 241 4096.
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doi:10.1016/j.febslet.2006.10.077about the molecular roles or fate of KLF6 in neoplastic cells
or in the response to anti-neoplastic therapies.
We found it notable to observe that KLF6 protein decreased
in all of several types of cancer cell lines in response to DNA
damage induced by cisplatin. The decrease in KLF6 protein
occurred only when the degree of DNA damage was extensive
enough to induce apoptosis. It occurred whenever apoptosis
was induced through the intrinsic pathway (i.e. DNA damage)
but not when induced through the extrinsic pathway (i.e. death
receptors). KLF6 was found to be ubiquitinated and to be
degraded by the proteasome.
Regulation of KLFs at the level of gene expression has been
well documented [12]. More recently, regulation at the protein
level has been reported for KLF1, KLF2, KLF5 and KLF4
[13–16]. The latter study used serum starvation as a means
of inducing growth arrest and demonstrated that under these
conditions KLF4 was degraded by the proteasome. Here, we
report similar ﬁndings for KLF6 in the setting of a cellular
perturbation with relevance for cancer biology, namely
chemotherapy/DNA damage induced apoptosis.2. Materials and methods
2.1. Cell lines and materials
HepG2 cells, IMR-90 and HCT116 cells were obtained from the
American Tissue Culture Collection (ATCC). Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM), McCoy’s 5A medium, antibiotics (penicil-
lin, streptomycin 100 mg/ml) and L-glutamine (30 mg/ml) were ob-
tained from Cellgro. Fetal bovine serum (FBS) was from Hyclone.
The polyclonal antibody anti-KLF6 (R-173) and anti p21 (C-19)
were obtained from Santa Cruz Biotechnology. Monoclonal antibody
recognizing the HA epitope was obtained from Santa Cruz. Secondary
antibodies were from Amersham. The proteasome inhibitors ALLN,
MG132 and lactacystine were obtained from Calbiochem. The caspase
inhibitor ZVAD-fmk was purchased from Alexis Biochemicals (San
Diego, CA). The calpain inhibitor calpeptin was from Sigma. Lipofect-
amine 2000 was obtained from Invitrogen.
2.2. Western blot analysis and chemiluminescence
Whole cell protein extracts were obtained by lysing cells in lysis buf-
fer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1%
NP40, 10% glycerol, 20 mM b-glycerolphosphate, 0.1 mM sodium
vanadate, 1 mM NaF, 1 mM PMSF and 1 protease inhibitor tablet/
10 mL buﬀer). For Western blot, 30–50 lg of total cell extracts were
resolved on a 10% SDS–PAGE. Following transfer onto nitrocellulose
membranes, proteins of interest were detected by incubating with pri-
mary antibodies and processed by the standard ECL detection method
under conditions recommended by the manufacturer (Amersham).
Nitrocellulose membranes were then subjected to chemiluminescenceblished by Elsevier B.V. All rights reserved.
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emitted light units were recorded by a digital camera, and quantitated.
2.3. Real-time quantitative PCR
Total cellular RNA was extracted using RNeasy Mini kit (Qiagen).
The RNA was treated with DNase (Qiagen). A total of 1 lg of RNA
was reverse transcribed per reaction using ﬁrst strand complementary
DNA synthesis with random primers (Promega). QRT-PCR was per-
formed using the following PCR primers on an ABI PRISM
7900HT Sequence Detection System (Applied Biosystems): KLF6 For-
ward: 5 0-CGG ACG CAC ACA GGA GAA AA-3 0 and KLF6 Re-
verse: 5 0-CGG TGT GCT TTC GGA AGT G-30. All experiments
were done in triplicates and normalized to actin. Fluorescent signals
were analyzed during each of 20 cycles consisting of denaturation
(95 C, 15 s), annealing (56 C, 15 s), and extension (72 C, 40 s).
2.4. Cell cycle analysis by ﬂow cytometry
For ﬂow cytometry analysis, cells were washed twice in PBS, trypsin-
ized with 1 ml of trypsin-EDTA, centrifuged, and washed in PBS once
more. Next, cells were resuspended in 250 ll of 1· PBS and 750 ll of
100% ethanol, which was added drop wise while cells were gently vor-
texed. To allow for proper ﬁxation, cells were kept on ice for at least
30 min, then centrifuged at 1000 rpm for 10 min at 4 C, washed twice
in PBS, and resuspended in 1 ml of PBS and RNaseA treated for
30 min in a 37 C water bath. Finally, cells were incubated with propi-
dium iodide and scanned by ﬂow cytometry using a Becton-Dickinson
Excalibur. A total of 10000 cells were analyzed per experiment.3. Results and discussion
3.1. Cisplatin induces degradation of KLF6 protein but only in
apoptotic doses
As in all human cancer cell lines, KLF6 is detected in
HCT116 cells as a double-band (Fig. 1A, lane 1). Both compo-
nents of the double-band are intensiﬁed when KLF6 is over-Fig. 1. Dose dependent bimodal response of KLF6 to DNA damage.
HCT116 cells were exposed to cisplatin and harvested 24 h later. (A)
50 lg of protein from total cell extracts were run on a 10% SDS–PAGE
gel and submitted to Western blot analysis for KLF6, PARP and p21.
Actin served as the protein loading control. KLF6 protein levels
increase with two low doses of cisplatin and decrease with two higher
doses. PARP cleavage occurred only with the high cisplatin doses
indicating that KLF6 induction occurred with sub-apoptotic doses of
cisplatin and decreased only with high, apoptotic doses. (B) Cell cycle
proﬁle of cells from the same culture dish after staining with propidium
iodide.expressed by transfected cDNA [10], suggesting that it is
derived from one transcript and represents two states of
posttranslational modiﬁcation. Exposure of HCT116 cells to
cisplatin 5–20 lM for 24 h led to arrest of the cell cycle in S
and G2 phase and induction of p21 but not to apoptosis as
shown by absence of PARP cleavage (Fig. 1, lanes 2 and 3).
Exposure to cisplatin to higher concentrations of 60–120 lM
led to apoptosis as shown by PARP cleavage and an increase
of the number of cells in the sub-G1 fraction of the DNA con-
tent proﬁle (lanes 4 and 5). These observations of cell cycle ar-
rest and apoptosis of HCT116 cells in the presence of the
concentrations of cisplatin used in this experiment is in accor-
dance with observations made by others [17]. The low molec-
ular component of the KLF6 double band disappeared at
60 lM and no KLF6 was detected at 120 lM, i.e. at apoptotic
cisplatin doses. We next investigated the cause of the decrease
in KLF6 protein by addressing whether the decline was due to
protein degradation or decrease in mRNA. HCT116 cells over-
expressing KLF6 were exposed to 120 lM cisplatin. As shown
in Fig. 2, we observed a decrease in KLF6 protein while
mRNA levels remained stable suggesting active degradation
of KLF6 protein upon exposure to cisplatin.
3.2. Cisplatin-induced KLF6 protein degradation is observed in
all cancer cell lines tested and with a variety of forms of
DNA damage
We were interested to investigate whether KLF6 degrada-
tion is universally observed in response to apoptotic doses of
DNA damage. Therefore, we tested diﬀerent cell lines, includ-
ing p53 deﬁcient HCT116 cells with diﬀerent genotoxic agents
to induce apoptosis. Table 1 summarizes all cell lines tested at
apoptotic doses of diﬀerent forms of genotoxic stress, includ-
ing drugs used in chemotherapy for cancer as well as ultravio-
let light (UVB). We observed degradation of KLF6 in all cell
lines once treatment was administered in doses that induced
apoptosis. Thus, although an earlier report noted that KLF6
protein disappeared after UVB and theorized that this could
facilitate cell-cycle reentry after DNA repair by releasing a
brake on c-jun [11] we found that doses of DNA damaging,
chemotherapeutic agents and UVB that lead to degradation
invariably lead to cell death while low doses that allow reentry
into the cell cycle are associated with an increase in KLF6 pro-
tein (Fig. 1 and Table 1).Fig. 2. KLF6 protein levels decrease due to accelerated protein
degradation. HCT116 cells were treated with 120 lM cisplatin and
submitted to Western Blot analysis (upper panel) and real time PCR
(lower panel). KLF6 protein disappeared but its mRNA remained
stable after exposure of the cells to extensive, apoptotic DNA damage
as indicated by PARP cleavage.
Table 1
Degradation of KLF6 () observed in multiple cell lines during apoptosis induction via the intrinsic/DNA damage pathway but not via the extrinsic/
death receptor pathway (() = stable KLF protein levels)
Cell lines Apoptotic agents Figures






Cisplatin UVB Other TNF-a Trail
Malignant Human Colon cancer HCT116 p53+/+    () () Figs. 1 and 4
p53/  () () Fig. 3
SW40 c-abl / p53mutant   Fig. 3
Hepatoblastoma HepG2    Fig. 3 and 7
Prostate cancer PC3-M    Not shown
Ovarian cancer Skov3   Not shown
Transformed Mouse Fibroblasts NIH3T3   Not shown
Human Embryonic kidney 293T  Not shown
Primary Human Fibroblasts IMR-90 Diploid   Fig. 3
GM09706 ATM/   Not shown
Mouse Embryonic ﬁbroblasts MEF Diploid  Not shown
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cancer cell lines, even among those of colonic origin [17,18].
Therefore, while some cell lines are more sensitive to cisplatin
than others (e.g. IMR-90 diploid ﬁbroblasts require less cis-
platin to undergo apoptosis within 24 h than HepG2 hepato-
blastoma cells), KLF6 degradation invariably occurs at
concentrations that ultimately lead to apoptosis. The rate of
the decline in KLF6 protein, a composite of protein degrada-
tion but stable levels of mRNA as shown in Figs. 2 and 3.
3.3. KLF6 degradation is speciﬁc for stimulation by the intrinsic
pathway and does not occur when apoptosis is induced by
TNF-a or TRAIL
Apoptosis can be induced via two principal pathways. Ultra-
violet irradiation and chemotherapeutic agents induce DNA
damage and induce apoptosis via the intrinsic apoptotic path-
way. Apoptosis that is triggered by stimulation of death recep-Fig. 3. KLF6 protein degradation after cisplatin occurs in all cell lines tested
cisplatin and submitted to Western Blot analysis. (B) Rate of KLF6 degradtors such as TNF-receptors, CD95, and TRAIL-receptors is
mediated via the extrinsic pathway. We tested whether the
decrease in KLF6 protein was a feature of apoptosis in general
or whether it would be limited to apoptosis triggered by DNA
damage. HCT116 cells are sensitive to the death receptor
ligands TRAIL and TNFa [19]. We therefore exposed
HCT116 cells to TNFa or TRAIL in the presence of cyclohex-
imide (CHX). For this experiment, TRAIL was used in combi-
nation with CHX because TRAIL can trigger a protective
pathway in via the activation of NFj-B, whose targets include
genes encoding intracellular inhibitors of apoptosis [20]. As
can be seen in Fig. 4, KLF6 protein levels remained stable
upon treatment of HCT116 cells with either ligand at doses
that induced a strong apoptotic response. CHX alone did
not induce apoptosis (data not shown). Thus, loss of KLF6
protein occurs in the setting of apoptotic DNA damage and
not with death receptor induced cell death.. (A) Cells were harvested 24 h after treatment with increasing doses of
ation.
Fig. 4. KLF6 level is stable upon stimulation the extrinsic apoptotic
pathway. KLF6 levels remain stable when the extrinsic pathway is
stimulated by TRAIL or TNFa. HCT116 human colon carcinoma
cells were treated with 50 ng/ml of TRAIL in the presence of 5 lg/ml of
CHX (A) or 100 ng/ml of TNFa (B). PARP cleavage is shown to
conﬁrm apoptotic cell death.
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proteasome
To assess the stability of KLF6 in untreated cells we inhib-
ited new protein synthesis with CHX. As shown in Fig. 5,
50% of KLF6 had disappeared after 16 min. The majority of
proteins in mammalian cells are degraded by the 26S protea-
some [21]. In this pathway, the protein is marked for recogni-
tion by the proteasome and subsequent degradation by
covalent linkage to multiple molecules of ubiquitin. To deter-
mine whether KLF6 is degraded by this mechanism we ﬁrstFig. 5. KLF6 half-life is increased by proteasome inhibition. (A) 293T
cells were transiently transfected with pcDNA3-Flag-KLF6 treated
with 100 lg/ml CHX to inhibit protein synthesis and submitted to
Western Blot analysis. (B) The quantity of KLF6 protein after CHX
treatment was determined by chemiluminescence and is shown relative
to the light emission of untreated cells. Quantiﬁcation was performed
for the combined lower and upper band. T1/2 was estimated to be
16 min. (C) Proteasome inhibition by ALLN 50 mM added 2 h prior to
the beginning of the experiment prevented KLF6 degradation
increasing the relative abundance of the upper component of the
KLF6 double band.determined the stability of KLF6 in the presence of the protea-
some inhibitor ALLN. Fig. 5 shows that KLF6 degradation in
normally proliferating cells was completely inhibited in the
presence of ALLN. We next examined whether KLF6 under-
goes ubiquitination. As seen in Fig. 6, a high molecular weight
smear, characteristic of ubiquitinated proteins is seen in 293T
cells co-transfected with Flag-tagged KLF6 and HA-tagged
ubiquitin. We conclude that KLF6 has a very short half-life
and that degradation occurs through the proteasome in nor-
mally proliferating cells.
To test whether KLF6 degradation after DNA damage also
occurs via the proteasome we treated cells with an apoptotic
dose of cisplatin in the presence of the proteasome inhibitor
lactacystine. As shown in Fig. 7, KLF6 levels were diminished
within 4 h and no KLF6 was detected after 18 h in cells treated
with cisplatin alone. However, cisplatin-mediated degradation
was completely inhibited in the presence of lactacystine. Simi-
lar results were obtained using two other proteasome inhibi-
tors, ALLN and MG132 (data not shown) but not with the
pan-caspase inhibitor Z-VAD-FMK or the calpain inhibitorFig. 7. KLF6 is degraded by the proteasome upon DNA damage.
HepG2 cells were treated with diﬀerent inhibitors of protein degrada-
tion 15 minutes prior to exposure to cisplatin (60 lM). (A) 40 lM of
Lactacystine prevented KLF6 degradation upon exposure to cisplatin.
(B) Degradation of KLF6 proceeded unaltered in the presences
Z-VAD-FMK (100 ng/ml), a pan-caspase inhibitor and prevented
PARP cleavage as shown. (C) There was no eﬀect by the calpain
inhibitor, calpeptin (40 lM).
Fig. 6. KLF6 is ubiquitinated in vivo. 293T cells were transiently
transfected with pcDNA-KLF6 and hemagglutinin-tagged ubiquitin
(pHA-Ub) and cultured for 2 h with the proteasome inhibitor ALLN
or vehicle alone (DMSO). Equal amounts of protein were immuno-
precipitated with anti-HA-antibody and Western blotted with anti
KLF6 or anti-Flag antibody.
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degraded by the proteasome after lethal DNA damage.
Protein degradation through the ubiquitin/proteasome path-
way is a key regulatory process in the control of apoptosis, cell
cycle control and DNA repair [22]. Degradation of proteins
that either promote DNA repair or are anti-apoptotic/pro-sur-
vival may precede cell death facilitating apoptosis when DNA
damage is too extensive to allow successful repair [23]. An
example of a DNA repair-related protein that is degraded in
this situation is PARP [24]. Two examples of anti-apoptotic
proteins that are degraded following DNA damage are c-FLIP
and Bcl2. Degradation of c-FLIP may contribute to sensitiza-
tion of cells towards apoptosis mediated by p53 [25]. In all of
these examples degradation is a speciﬁc regulatory event and
not the consequence of unspeciﬁc processes. In the present
study, we showed KLF6 levels are controlled by proteasomal
degradation linked to DNA damage. Low levels of DNA dam-
age that induced p21 and shifted the cell cycle towards the G2
phase led to a moderate increase of KLF6. High levels of DNA
damage had the opposite eﬀect inducing complete loss of
KLF6 by accelerated proteasomal degradation. KLF6 levels
were unaﬀected when apoptosis was induced by TRAIL or
TNF-a, which act through the extrinsic pathway. The observa-
tions were consistent across various forms of DNA damage
and many diﬀerent human cell lines. Based on our ﬁndings
one could hypothesize that KLF6 might have a role in the cel-
lular response to DNA damage.
Although other factors may also contribute to the downreg-
ulation of KLF6 the present study presents evidence that post-
translational modiﬁcation by ubiquitin and proteasomal
degradation is an important mechanism determining KLF6
levels. Given recent reports correlating decreased KLF6 levels
in primary human tumors with poor patient survival [7,26] it is
interesting to speculate that alterations in KLF6 degradation
in malignant tissues may aﬀect the cancer phenotype. In sum-
mary, although molecular details of how KLF6 regulates the
cell cycle and apoptosis are still poorly understood, the present
study indicates that destabilization of KLF6 protein in
response to stimulation of the intrinsic apoptotic pathway
occurs, at least partially, by ubiquitin-mediated proteasomal
degradation. Further studies will be necessary to elucidate
the molecular mechanisms directing KLF6 ubiquitination,
e.g. identiﬁcation of the responsible E3-ligase and to deﬁne
the possible contribution of KLF6 destabilization to the cellu-
lar response towards DNA damage or resistance to degrada-
tion to the malignant phenotype.
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